Those worries about Alan Feuerstein's remarks should not. I have known the guy for years and he knows very little about medicine, clinical trials, or biotechnology in general. He has embarrassed himself many times at conferences and there are few CEO's or doctors who bother to listen or speak with him. Many, including myself, find him dangerous. But his record speaks for itself.
Here's the paragraph that relates to IMUC, "Despite a lot of convincing evidence debunking the vaccine approach to cancer immunotherapy, tiny biotech companies push ahead -- NewLink, Galena Biopharma (GALE_), Vical (VICL_), Northwest Biotherapeutics (NWBO_), ImmunoCellular Therapeutics (IMUC_). I'm not a believer. I'll be happy to admit my error if/when one of these companies produces boffo clinical data. I just don't see that happening anytime soon."
It is in his weekly Biotech Stock Mailbag posted yesterday where he discusses NewLink and immonotherapies in general. This guy is always a sceptic with this kind of companies and mainly expresses his opinion not backed by specific facts but often fun to read anyhow. Will be intersting to see how he changes his mind when any of those companies (like IMUC) show postive results in P3 or larger randomized P 2 studies.